鈴木 憲史 すずき けんし 先生

来歴等

略歴

1976年　国立新潟大学医学部卒業
1976年　日本赤十字社医療センター内科研修医
1978年　日本赤十字社医療センター内科医師
1982年　国立東京医科歯科大学医学部大学院専攻科 終了
1984年　国立東京大学医学部第３内科（血液学専攻）研究生 終了
1990年　日本赤十字社医療センター第2内科副部長
1995年　日本赤十字社医療センター第2内科（血液）部長
2012年　日本赤十字社医療センター副院長　(平成28年定年)
2014年　日本赤十字社医療センター薬剤部長兼務
2016年　日本赤十字社医療センター骨髄腫アミロイドーシスセンターセンター長・薬剤部長・輸血部長

論文

1) Y.Eishi, K.Suzuki, S.Hatakeyama . Freeze-Preservation of staining solutions in enzyme histochemistry. Bull Tokyo Med and Dent Univ 29;47-52, 1982.
2) K.Suzuki, K.Hirokawa, S.Hatakeyama. Age-related change of distribution of immunoglobulin containing cells in human bone marrow –Changes in patients with benign monoclonal gammopathy and multiple myeloma Virchows Arch(Pathol Anat)404;243-251,1984. 【学位主論文】
3) K.Suzuki, T.Takemura, R.Okeda, S.Hatakeyama. Vascular changes of Methotrexate-related disseminated necrotizingLeukoencephalogy　 Acta Neuropathol　(Berl)65;145-149, 1984.【学位副論文】

6) K.Suzuki, K.Hirokawa, R.Kamiyama, S.Hatakeyama. Distribution of immunoglobulin containing cells in human bone marrow of patients with leukemia. Acta Pathol Jpn 37; 193-199, 1987.
７) K.Suzuki, K.Hirokawa, T.Takemura, Y.Esaki. Age-related change in the number of mast cells in human bone marrow and spleen. Acta Haematol Jpn 51;739-745, 1988.
53）K Suzuki: Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol. 16:659-671, 2012
54) K Suzuki: Current therapeutic strategy for Multiple myeloma. Jpn J Clin Oncol 43:116-124, 2013
55) K Suzuki: Diagnosis and Treatment of Multiple Myeloma and AL Amyloidosis with Focus on Improvement of Renal Lesion　6thAnnual World Cancer Congress-2013 Xian ,China 23/May/2013
56) Ogawa Y,　Suzuki　K,　Hotta　T　et　al:　Phase　1/2　study　of　bortezomib　 -melphalan- Prednisolone　for　previously　untreated Japanese patients with multiple myeloma. Cancer Science, doi:10.1111/cas.12172,2013
57)Nakagawa　Y, K Suzuki., Masaoka T et al: Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neiutropenia. J Infect Chemother 19:103-111,2013.
２０１４
58)Ozaki S, Harada T, Saitou T, Suzuki　K　et al: Survival of multiple myeloma patients aged 65-70 years in the Era of novel agents aqnd autologous stem cell transplantation. Acta Hematol. 132:211-219,2014
59) Kim K, Lee H, Kim JS, Suzuki　K, et al: Clinical profiles of multiple myeloma in Asia-An Asian myeloma network study. Am J Hematol 89:751-756, 2014
60) Miyazaki K, Suzuki K: Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: A rare case. Acta Hematol 132:68-72,2014
61) Handa H, Suzuki K, Chou T, et al. Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide–Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2014; 124, 5752
２０１５
62) K Suzuki, M Ogura, Y Abe, A phase 1 study of siltuximab, an anti-IL-6 mAb, in relapsed/ refractory multiple myeloma. Int J Hematol 2015 Mar;101(3):286-94　
63) Miyazaki K, Suzuki K: Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis　Int J Myel 5(3): 30–35, 2015
64) Miyazaki K, S Kawai, K Suzuki: Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry. Int J Hematol 102:289-295,2015
65) Meshitsuka S, K Suzuki,: The efficacy and safety of a 1.6 mg/㎡ increase in a bortezomib regimens. Open J Blood Diseases 2015
J Inoue, M Ikeda, K Suzuki, et.al: The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma. Rinshou ketueki 56:2311-2317,2015
66) Watanabe T, Suzuki K, Kizaki M.　et al: Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.
PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. eCollection 2015.
67) Ozaki S, Suzuki K, Shimizu K. et al: Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015 Sep 18;5:e349. doi: 10.1038/bcj.2015.79.
２０１６
68)Watanabe T, K Suzuki, Iida S：A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56.
69) Suzuki K, Shinagawa A, Chou T. et al: Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Cancer Sci. 2016 May;107(5):653-8.
７０）Miyazaki　K, K Suzuki:　Capillary electrophoresis/immunosubtraction　as　a　better　alternative　to　immunofixation　for　detecting　and　immunotyping　serum　monoclonal　proteins　in　patients　with　immunoglobulin　light　chain　(AL)　amyloidosis.　Amyloid 2016 DOI:10.1080/13506129
71) Suzuki K, et al Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci. 2016, doi: 10.1111/cas,12916.
72) Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y.: Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. Int J Hematol. 2016 Jan;103(1):79-85.
73）Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K.
: High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. Int J Hematol. 2016
Mar;103(3):299-305.
74) Mu S, Kuroda Y, Suzuki K et al: Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Eur J Clin Pharmacol. 2016 Feb;72(2):153-61.
75) Ichinohe T, Kuroda Y, Suzuki K. et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol 2016.5:11 Doi 10.1186.
76) Suzuki K, Masaki Ri, T Chou, et al: Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma: A multicentre, open-label, phase 1 study in Japan　(2016)
77)　Ikeda M, Tukada N, Suzuki K et al: Successful second allogeneic stem cell transplantation from a sibling donor for relapse of myelodysplastic syndrome in a recipient of a remnal transplant from his mother ; case report. Transplantation Proceedings 2016:48,3085-3087.
78)Kitamura K, Nishiyaka T, Suzuki K et al:Clinical usefulness of WT 1 mRNA expression in bone marrow detected by a new WT 1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT 1 mRNA in peripheral blood. Int J Hematol 2016,103:53-62.
79) Dimopoulos MA, Suzuki K. Moreau P et al: An Open-label, Randomised, Phase 3 Study of saftytumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX NEJM: N Engl J Med. 2016 Oct 6;375(14):1319-1331.
80) Suzuki K, Hiroshi Handa, Takaaki Chou, et al: A Phase 1 Study of Ixazomib Alone or Combined with Lenalidomide- Dexamethasone in Japanese Patients with Relapsed/Refractory Multiple Myeloma (2016)
２０１７
81）Iki S, Ohgi K, Suzuki K;　Eculizumab　treatment　improved　renal　hemosiderosis　in　a　patient　with　paroxysmal　nocturnal　hemoglobinuria. Int J Hematol 2017 105:231-232
82） Miyazaki K, Suzuki K.: Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis.　 Amyloid. 2016 Sep 28:1-4.
83） Meshitsuka S, Shingaki S, Suzuki K, et al; Phase 2 trial of daily, oral epigallocatechin gallate in patients with light‑chain amyloidosis Int J Hematol DOI 10.1007/s12185-016-2112-1, 2016
84) Suzuki K, Sunami K, Taniwaki M.et al: Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
Blood Cancer J. 2017 Mar 10;7(3): e540. doi: 10.1038/bcj.2017.18. No abstract available.
85) Suzuki K, Ri M, Iida S. et al: Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Cancer Sci. 2017 Mar;108(3):461-468.
86) Suzuki K, Handa H, Kase Y. et al: Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Int J Hematol. 2017 Apr;105(4):445-452.
87)Shingaki S, Tukada N, Suzuki K et al; Feasibility of myeloablative allogenic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma. Hematological Oncology 2017, 1-3: July
88) Futami M, Sato K, Miyazaki K, Suzuki K, Nakamura T, Tojo A.et al: Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.
Mol Ther Oncolytics. 2017 Jul 22;6:57-68.
８９) Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.et al: Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.　N Engl J Med. 2017 Dec 12.
２０１8
９０）Miyazaki K, Suzuki K.; Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis. Intern Med. 2018 Mar 15;57(6):775-776. doi: 10.2169/internalmedicine.9511-17. Epub 2018 Jan 11. No abstract available.
9１) Kawamura K, Tsukada N, Kanda Y, Ikeda T, Yoshida A, Ueda Y, Ishida T, Suzuki K, Murakami H. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biol Blood Marrow Transplant. 2018 Mar 16. pii: S1083-8791(18)30125-3. doi: 10.1016/j.bbmt.2018.03.012. [Epub ahead of print]
9２) Ri M, Suzuki K, Iida S, Hatake K, Chou T, Taniwaki M, Watanabe N, Tsukamoto T. A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Intern Med. 2018 Apr 1;57(7):939-946. doi: 10.2169/internalmedicine.9567-17. Epub 2017 Dec 8.
9３) Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.
9４)Iyoda T , Yamasaki S , Hidaka, M , Kawano F , Abe Y , Suzuki, K , et al. Amelioration of NK cell function driven by Vα24+ invariant NKT cell activation in multiple myeloma. Clinical Immunology 2018 Feb, 187:76-84
9５） Tan D , Lee J H , Chen W , Shimizu K , Hou J , Suzuki K , et al. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Leukemia and Lymphoma 2018 Feb 2, 1-13
9６)Miyazaki K, Suzuki K. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients ｗith Multiple Myeloma With Deep Responses. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):293-296.
doi: 10.1016/j.clml.2018.01.008. Epub 2018 Feb 19.
９７) Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.